| |
September 26, 2023 | 1:00 PM ET Planning to commercialize a gene therapy product? Learn how you can maximize revenue potential and navigate the market’s unique challenges with Trinity Life Sciences. Ready to tackle the elephant? Register Now. .png)
|
|
Today’s Big NewsAug 29, 2023 |
|
Understand how to navigate EU regulations to launch rare disease medicines in European markets. Download guide. 
|
|
|
 Thank you to Bridge Bank for sponsoring our editorial feature: Fierce 15
|
|
| By Nick Paul Taylor LIB Therapeutics has passed another milestone on its path to launching a challenger to cholesterol drugs sold by Amgen, Regeneron and Sanofi. In the latest phase 3 readout, the private biotech’s subcutaneous PCSK9 inhibitor cut levels of LDL cholesterol to maintain momentum going into the final two data drops. |
|
|
|
| Philadelphia, PA |  |
|
|
By James Waldron While it continues to hone in on the cause of a rare side effect linked to its geographic atrophy drug Syfovre, Apellis has decided to lay off a quarter of its workforce and cull its two preclinical assets to claw back $300 million in savings. |
By Annalee Armstrong This year's Fierce 15 features companies pushing the envelope not only in the lab, in the clinic or on the conference circuit. |
Sponsored by Novartis Global Biotech Cooperations With the rapid increase in cell and gene manufacturing, companies need support from experienced, reliable, and global, CDMO's with a deep and rich technology network. |
By Max Bayer A group of activist investors is once again taking on AIM Immunotech's leadership, suing the company for changes to its bylaws made earlier this year. The company rejected three board nominations earlier this month. |
Sponsored by IPM.ai Using artificial intelligence to predict and uncover de-identified rare disease patients shortens the time to diagnosis, benefiting both patients and life science companies. |
By Nick Paul Taylor Clene has shared another cut of long-term data from its phase 2 amyotrophic lateral sclerosis (ALS) trial. The open-label extension linked a gold nanocrystal suspension to improved survival, but, with setbacks including a primary endpoint miss hanging over it, Clene’s share price remains in the basement. |
By Helen Floersh It's hard enough to juggle two experiments at once. Now, try to imagine managing 200 of them—in space. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson Fierce Biotech's M&A Tracker, your one-stop shop for dealmaking in the biopharma universe. |
By Helen Floersh New research that helps explain why KRAS mutations drive pancreatic cancer suggests that monotherapy isn’t sufficient to eliminate it—but that combining KRAS inhibitors with immunotherapy might be the key. |
By Ben Adams Many survivors of heart attacks or strokes remain uncertain about the risks associated with "bad cholesterol" or their LDL levels. |
By Noah Tong Obesity impacts roughly 40% of Americans, but insurers are becoming less willing to cover weight loss drugs for the disease. Health companies are looking to bridge the gap. |
By Fraiser Kansteiner The drugs that made the cut for the first price negotiations are Johnson & Johnson’s Imbruvica, Stelara and Xarelto plus Bristol Myers Squibb’s Eliquis, Merck & Co.’s Januvia, Novartis’ Entresto, Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Novo Nordisk’s Fiasp and Amgen’s Enbrel. |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|
